Ipilimumab (Yervoy) is a monoclonal antibody directed against cytotoxic T-lymphocyte antigen 4 (CTLA-4). It was the first drug to demonstrate a survival benefit in advanced melanoma and was approved by the FDA in 2011.1 By blocking the CTLA-4 receptor, ipilimumab enhances the immune response against tumors via cytotoxic T lymphocyte activation and proliferation.2 However, immunopotentiating…
Search results for: back pain
Rheumatology Drug Updates: Sirukumab Promising for RA, Plus Efficacy Duration of Ustekinumab for Plaque Psoriasis
Sirukumab Promising for RA Sirukumab, an investigational human monoclonal antibody that selectively binds to the interleukin (IL) 6 cytokine, has completed a randomized, double-blind, placebo-controlled, parallel-group, Phase 3 clinical trial (SIRROUND-T) in patients with rheumatoid arthritis (RA).1 During the trial, which took place between July 25, 2012, and Jan. 12, 2016, researchers randomized adult patients…
Experimental Drug Combination Curbs Chikungunya Arthritis in Mice
Doctors have had few options to treat the chronic rheumatoid arthritis-like symptoms associated with chikungunya virus infections beyond over-the-counter pain relievers. A recent study in Science Translational Medicine has spurred new optimism by finding that a combination therapy—the anti-rheumatic drug abatacept paired with a chikungunya-neutralizing monoclonal antibody—abolished acute symptoms in infected mice.1 The strategy must…
FDA Approves Oral Methotrexate; Plus Restrictions for 2 Analgesics in Children
The FDA has approved a new formulation of methotrexate designed as an oral solution for pediatric patients. The agency has also recently introduced age restrictions for codeine and tramadol for children under age 12, citing their risks for slowed or difficult breathing and death…
Strategies for Successful Joint Replacement Surgery
Collaboration among all providers—surgeon, rheumatologist, physical therapist, etc.—is essential for patients with a rheumatic disease who are about to undergo total joint arthroplasty to reach their goals, including reduced pain and improved mobility…
Surgery Won’t Help Degenerative Knee Problems
(Reuters Health)—Arthroscopic surgery won’t cure chronic knee pain, locking, clicking, a torn meniscus or other problems related to knee arthritis, according to a panel of international experts. Every year, more than two million people with degenerative knee problems have arthroscopic surgery. But guidelines published May 10 in the British Medical Journal recommend against the procedure…
Lifetime Risk of Hand Arthritis May Be More Than 40%
(Reuters Health)—A new study finds that as many as four in 10 people may develop hand osteoarthritis. Among women, researchers found the lifetime risk was 47% while for men it was about 25%. Obese people also had 11% higher lifetime risk than those who were not obese. Hand osteoarthritis can cause disability and problems with…
Complex Treatment: Cancer, Immunotherapy & Rheumatic Disease
Some cancer patients taking immune checkpoint inhibitors experience immune-related adverse events. Laura C. Cappelli, MD, MHS, says rheumatologists are natural partners with oncologists to treat this patient population…
MicroRNAs Provide Insight into Bone Metabolism
A recent study examined the functional variants within microRNAs that affect bone metabolism and possibly bone disorders. Researchers found overexpression of microRNAs may contribute to the osteoporotic phenotype, and the gene targets associated with two specific osteoblast-expressed microRNAs may be critical in osteoporosis…
A Moving Target: Cardiovascular Risk & Rheumatic Disease
For patients with rheumatic disease, general treatment guidelines for managing cardiovascular risk are suboptimal, says Katherine Liao, MD. A patient’s level of disease activity and inflammation affect their risk…
- « Previous Page
- 1
- …
- 110
- 111
- 112
- 113
- 114
- …
- 155
- Next Page »